Background The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …

… (MPR) with or without lenalidomide maintenance (MPR-R). Primary end point was PFS
and MPR-R resulted superior than MPR and MP (31 vs. 14 vs. 13 months, respectively). …

In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical
component for novel therapeutic strategies. This dysfunction is due to a reduced antigen …

… to a significantly lower rate of early relapse in R-ISS Stage 2/3 pts receiving KRd_ASCT_KRd
vs KRd12 (11 pts [12%] vs 22 pts [23%]; P=0.05); no difference was seen in R-ISS 1 (0 vs 2 …

… Methods: A phase 3 study was designed to compare [random (R) 1] 4 cycles of
bortezomib-melphalan-prednisone (VMP) vs high-dose melphalan (HDM) and single or double …

Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most
effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD …

… ) compared with chemotherapy plus lenalidomide (CC+ R). Salvage ASCT at first relapse
may … vs CC+ R and the impact of salvage ASCT in patients who received upfront CC+ R, we …

… Prespecified subgroup analyses of PFS confirmed that the benefit associated with ASCT
was not influenced by revised ISS (R-ISS) disease stage (stage II: P=0.006; stage III: P<0.001), …

Background The role of single vs double autologous stem cell transplantation (ASCT) in
patients with newly diagnosed (ND) multiple myeloma (MM) needs to be prospectively …

PURPOSE To address the role of consolidation treatment for newly diagnosed, transplant
eligible patients with multiple myeloma in a controlled clinical trial. PATIENTS AND METHODS …